力生製藥(002393.SZ):吲達帕胺緩釋片通過藥品上市許可申請
格隆匯7月2日丨力生製藥(002393.SZ)公佈,近日,公司收到國家藥品監督管理局頒發的關於吲達帕胺緩釋片(以下簡稱"該藥品")1.5mg規格的《藥品註冊證書》(批件編號:2024S01229),該藥品通過藥品上市許可申請。
吲達帕胺緩釋片適應症:用於成人原發性高血壓的治療。根據IMS數據顯示,吲達帕胺緩釋製劑2022年全球銷售額為3.76億美元。根據米內網數據庫顯示,吲達帕胺緩釋製劑2022年、2023年國內銷售額分別為人民幣2.35億元和2.19億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.